Dairy Choline Bioavailability
Launched by UNIVERSITY OF WISCONSIN, MADISON · Mar 24, 2025
Trial Information
Current as of April 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial, called "Dairy Choline Bioavailability," is exploring whether dairy products, specifically a type of whey protein, are as good a source of choline as eggs for post-menopausal women. Choline is an important nutrient that our bodies need for various functions, and the researchers want to understand how our bodies use it. Participants will be asked to drink a chocolate-flavored beverage that contains either whey protein phospholipid concentrate (WPPC) or whole egg powder to see how effective each source is for choline absorption.
To be eligible for this study, women aged 51 to 70 who are post-menopausal can participate, provided they are not allergic to dairy or eggs and have maintained a stable body weight for the last six months. Participants will need to complete health surveys, keep a food diary for four days, and provide samples of blood, urine, and stool at the start and after 10 days of drinking the study beverages. It's important for participants to be in good health, free from certain medical conditions, and willing to avoid rigorous exercise during the study. This research could help us understand more about the best sources of choline for women in this age group.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Ages between 51 and 70
- • Is currently post-menopausal (Post-menopausal is a term used to describe the time in a woman's life after she has gone through menopause. This usually happens between the ages of 45 and 55. Menopause is when a woman's menstrual periods stop permanently (at least 12 months))
- • Not allergic to the intervention foods and allergens that are related to the production of intervention foods (e.g. dairy products, egg, fish, peanut, shellfish, soy, tree nuts, wheat, crustaceans, gluten, mollusks, mustard, sesame seeds.)
- • Had stable body weight (± 5%) for the past 6 months
- • Free from cancer
- • Did not have weight loss surgery, colon surgery
- • Do not have chronic kidney diseases
- • Do not have malabsorption towards fat and dairy products
- • Willing to complete health surveys
- • Willing to complete two 4-day food records
- • Willing to consume the chocolate-flavored intervention beverages
- • Willing to provide blood, urine, fecal samples at baseline and after 10 days of intervention
- Exclusion Criteria:
- • On weight loss/weight gain diets
- • Diagnosed with fat malabsorption
- • Undergoing weight loss surgery
- • Diagnosed with chronic kidney diseases
- • Allergic to the intervention foods and allergens that are related to the production of intervention foods (e.g. dairy products, egg, fish, peanut, shellfish, soy, tree nuts, wheat, crustaceans, gluten, mollusks, mustard, sesame seeds.)
- • Regularly using antibiotics or probiotics or prebiotics
- • Regularly using Orlistat or Cetilistat
- • Regularly using laxatives
- • Undergoing hormone replacement therapy, or receiving hormones in any forms
- • Unable to avoid strenuous exercise during the study (\>4 h intense exercise per day)
About University Of Wisconsin, Madison
The University of Wisconsin-Madison is a leading research institution renowned for its commitment to advancing healthcare through innovative clinical trials. With a strong emphasis on interdisciplinary collaboration, the university leverages its extensive resources, including cutting-edge facilities and a diverse pool of expert researchers, to conduct rigorous studies that address critical health challenges. The institution's focus on translating research findings into practical applications fosters the development of new treatments and interventions, ultimately contributing to improved patient outcomes and public health initiatives. As a sponsor of clinical trials, the University of Wisconsin-Madison is dedicated to upholding the highest ethical standards and ensuring participant safety throughout the research process.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Madison, Wisconsin, United States
Patients applied
Trial Officials
Bradley Bolling, PhD
Principal Investigator
University of Wisconsin, Madison
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported